A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia.
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2016
At a glance
- Drugs Ofatumumab (Primary) ; Bortezomib
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 05 Apr 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Feb 2014 as per ClinicalTrials.gov record.
- 24 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.